• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer.预测食管癌患者术前放化疗后病理完全缓解的临床参数模型。
Ann Oncol. 2012 Oct;23(10):2638-2642. doi: 10.1093/annonc/mds210. Epub 2012 Jul 24.
2
The Incremental Value of Subjective and Quantitative Assessment of 18F-FDG PET for the Prediction of Pathologic Complete Response to Preoperative Chemoradiotherapy in Esophageal Cancer.18F-FDG PET主观与定量评估对预测食管癌术前放化疗病理完全缓解的增量价值
J Nucl Med. 2016 May;57(5):691-700. doi: 10.2967/jnumed.115.163766. Epub 2016 Jan 21.
3
Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort.胃癌和食管癌患者术前放化疗后临床完全缓解与病理完全缓解的相关性:大型队列分析。
Ann Oncol. 2013 May;24(5):1262-6. doi: 10.1093/annonc/mds617. Epub 2012 Dec 17.
4
Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response.食管癌术前放化疗后病理完全缓解的特征及病理完全缓解后的结局
Cancer. 2005 Dec 1;104(11):2365-72. doi: 10.1002/cncr.21439.
5
Results of the baseline positron emission tomography can customize therapy of localized esophageal adenocarcinoma patients who achieve a clinical complete response after chemoradiation.基线正电子发射断层扫描的结果可以为接受放化疗后获得临床完全缓解的局限性食管腺癌患者的治疗提供定制化方案。
Ann Oncol. 2013 Nov;24(11):2854-9. doi: 10.1093/annonc/mdt340. Epub 2013 Aug 29.
6
A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer.一项关于诱导化疗与无诱导化疗后行术前放化疗治疗食管癌的 II 期随机临床试验。
Ann Oncol. 2013 Nov;24(11):2844-9. doi: 10.1093/annonc/mdt339. Epub 2013 Aug 23.
7
Histologic subtypes as determinants of outcome in esophageal carcinoma patients with pathologic complete response after preoperative chemoradiotherapy.组织学亚型作为术前放化疗后病理完全缓解的食管癌患者预后的决定因素。
Cancer. 2006 Feb 1;106(3):552-8. doi: 10.1002/cncr.21601.
8
Pathological complete response in patients with esophageal cancer after the trimodality approach: The association with baseline variables and survival-The University of Texas MD Anderson Cancer Center experience.三联疗法后食管癌患者的病理完全缓解:与基线变量及生存情况的关联——得克萨斯大学MD安德森癌症中心的经验
Cancer. 2017 Nov 1;123(21):4106-4113. doi: 10.1002/cncr.30953. Epub 2017 Sep 8.
9
Nuclear expression of Gli-1 is predictive of pathologic complete response to chemoradiation in trimodality treated oesophageal cancer patients.Gli-1的核表达可预测接受三联疗法治疗的食管癌患者对放化疗的病理完全缓解情况。
Br J Cancer. 2017 Aug 22;117(5):648-655. doi: 10.1038/bjc.2017.225. Epub 2017 Jul 20.
10
Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation.局限性食管癌的基因表达谱分析:与术前放化疗病理反应的关联
J Clin Oncol. 2006 Jan 10;24(2):259-67. doi: 10.1200/JCO.2005.03.3688. Epub 2005 Dec 12.

引用本文的文献

1
TP53-centric ctDNA complements PET/CT for non-invasive assessment of pathological complete response and survival after neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma: a prospective cohort study.以TP53为中心的循环肿瘤DNA(ctDNA)辅助正电子发射断层扫描/计算机断层扫描(PET/CT)对食管鳞状细胞癌新辅助免疫化疗后的病理完全缓解和生存情况进行无创评估:一项前瞻性队列研究
Int J Surg. 2025 May 1;111(5):3256-3268. doi: 10.1097/JS9.0000000000002341.
2
Nomogram for predicting pathologic complete response following preoperative chemoradiotherapy in patients with esophageal squamous cell carcinoma.预测食管鳞状细胞癌患者术前放化疗后病理完全缓解的列线图
Gastroenterol Rep (Oxf). 2024 Jul 6;12:goae060. doi: 10.1093/gastro/goae060. eCollection 2024.
3
Pathologic complete response in patients with esophageal cancer receiving neoadjuvant chemotherapy or chemoradiation: A systematic review and meta-analysis.接受新辅助化疗或放化疗的食管癌患者的病理完全缓解:系统评价和荟萃分析。
Cancer Med. 2024 Feb;13(4):e7076. doi: 10.1002/cam4.7076.
4
Perioperative therapy landscape for locally advanced, resectable esophageal cancer: an updated literature review.局部晚期可切除食管癌的围手术期治疗现状:文献综述更新
J Thorac Dis. 2023 Jun 30;15(6):3466-3487. doi: 10.21037/jtd-23-27. Epub 2023 Jun 13.
5
F-FDG-PET/CT to Detect Pathological Complete Response After Neoadjuvant Treatment in Patients with Cancer of the Esophagus or Gastroesophageal Junction: Accuracy and Long-Term Implications.氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描(F-FDG-PET/CT)用于检测食管或胃食管交界处癌患者新辅助治疗后的病理完全缓解:准确性和长期影响。
J Gastrointest Cancer. 2024 Mar;55(1):270-280. doi: 10.1007/s12029-023-00951-2. Epub 2023 Jul 1.
6
Nomogram for Predicting Pathologic Response Following Neoadjuvant Chemotherapy or Chemoradiotherapy in Patients with Esophageal Cancer.预测食管癌患者新辅助化疗或放化疗后病理反应的列线图
Ann Surg Oncol. 2023 Apr;30(4):1945-1947. doi: 10.1245/s10434-023-13133-y. Epub 2023 Jan 30.
7
Tri-modality therapy in advanced esophageal carcinoma: long-term results and insights from a developing world, institutional cohort.三模态疗法治疗晚期食管癌:发展中国家机构队列的长期结果和见解。
Br J Radiol. 2023 Mar;96(1143):20220413. doi: 10.1259/bjr.20220413. Epub 2023 Jan 12.
8
Prognostic values of the gross volume of metastatic lymph nodes in patients with esophageal squamous cell carcinoma treated with definitive concurrent chemoradiotherapy.接受根治性同步放化疗的食管鳞状细胞癌患者中转移性淋巴结总体积的预后价值。
Front Oncol. 2022 Nov 10;12:996293. doi: 10.3389/fonc.2022.996293. eCollection 2022.
9
Trimodality Therapy vs Definitive Chemoradiation in Older Adults With Locally Advanced Esophageal Cancer.三模态疗法与确定性放化疗治疗局部晚期老年食管癌的比较。
JNCI Cancer Spectr. 2022 Nov 1;6(6). doi: 10.1093/jncics/pkac069.
10
Prediction of pathologic complete response prediction in patients with locally advanced esophageal squamous cell carcinoma treated with neoadjuvant immunochemotherapy: A real-world study.新辅助免疫化疗治疗局部晚期食管鳞癌患者病理完全缓解预测的真实世界研究。
Biomol Biomed. 2023 Feb 1;23(1):153-160. doi: 10.17305/bjbms.2022.7696.

本文引用的文献

1
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.2008 年全球癌症负担估计值:GLOBOCAN 2008。
Int J Cancer. 2010 Dec 15;127(12):2893-917. doi: 10.1002/ijc.25516.
2
The standardized uptake value of 18-fluorodeoxyglucose positron emission tomography after chemoradiation and clinical outcome in patients with localized gastroesophageal carcinoma.放化疗后 18 氟-脱氧葡萄糖正电子发射断层扫描标准化摄取值与局限性胃食管癌患者临床结局的关系。
Oncology. 2010;78(5-6):316-22. doi: 10.1159/000319938. Epub 2010 Aug 11.
3
Resectable esophageal cancer: surgery as primary therapy is not the answer, but then, what is and why?可切除食管癌:手术作为主要治疗方法并非答案,那么,什么是答案以及为何如此?
J Clin Oncol. 2010 May 20;28(15):e243-4; author reply e245. doi: 10.1200/JCO.2009.26.7591. Epub 2010 Apr 5.
4
Trimodality therapy without a platinum compound for localized carcinoma of the esophagus and gastroesophageal junction.局部食管癌和胃食管交界处癌的无铂三联疗法。
Cancer. 2010 Apr 1;116(7):1656-63. doi: 10.1002/cncr.24935.
5
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.一项关于食管癌术前化疗与否的手术随机试验的长期结果
J Clin Oncol. 2009 Oct 20;27(30):5062-7. doi: 10.1200/JCO.2009.22.2083. Epub 2009 Sep 21.
6
The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma.放化疗后正电子发射断层扫描标准化摄取值的下降幅度越大,胃食管腺癌患者的生存率越高。
Cancer. 2009 Nov 15;115(22):5184-92. doi: 10.1002/cncr.24604.
7
Impact of tumor length on long-term survival of pT1 esophageal adenocarcinoma.肿瘤长度对pT1期食管腺癌长期生存的影响。
J Thorac Cardiovasc Surg. 2009 Oct;138(4):831-6. doi: 10.1016/j.jtcvs.2009.02.003. Epub 2009 Apr 9.
8
Worldwide esophageal cancer collaboration.全球食管癌协作组织
Dis Esophagus. 2009;22(1):1-8. doi: 10.1111/j.1442-2050.2008.00901.x.
9
Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival.食管癌新辅助放化疗后的完全病理缓解与生存率提高相关。
Ann Thorac Surg. 2009 Feb;87(2):392-8; discussion 398-9. doi: 10.1016/j.athoracsur.2008.11.001.
10
Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age.美国白人中按性别、分期和年龄划分的食管腺癌发病率。
J Natl Cancer Inst. 2008 Aug 20;100(16):1184-7. doi: 10.1093/jnci/djn211. Epub 2008 Aug 11.

预测食管癌患者术前放化疗后病理完全缓解的临床参数模型。

Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer.

机构信息

Departments of Gastrointestinal Medical Oncology, Houston, USA.

Departments of Thoracic and Cardiovascular Surgery, Houston, USA.

出版信息

Ann Oncol. 2012 Oct;23(10):2638-2642. doi: 10.1093/annonc/mds210. Epub 2012 Jul 24.

DOI:10.1093/annonc/mds210
PMID:22831985
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3457750/
Abstract

BACKGROUND

Approximately 25% of patients with esophageal cancer (EC) who undergo preoperative chemoradiation, achieve a pathologic complete response (pathCR). We hypothesized that a model based on clinical parameters could predict pathCR with a high (≥60%) probability.

PATIENTS AND METHODS

We analyzed 322 patients with EC who underwent preoperative chemoradiation. All the patients had baseline and postchemoradiation positron emission tomography (PET) and pre- and postchemoradiation endoscopic biopsy. Logistic regression models were used for analysis, and cross-validation via the bootstrap method was carried out to test the model.

RESULTS

The 70 (21.7%) patients who achieved a pathCR lived longer (median overall survival [OS], 79.76 months) than the 252 patients who did not achieve a pathCR (median OS, 39.73 months; OS, P = 0.004; disease-free survival, P = 0.003). In a logistic regression analysis, the following parameters contributed to the prediction model: postchemoradiation PET, postchemoradiation biopsy, sex, histologic tumor grade, and baseline (EUS)T stage. The area under the receiver-operating characteristic curve was 0.72 (95% confidence interval [CI] 0.662-0.787); after the bootstrap validation with 200 repetitions, the bias-corrected AU-ROC was 0.70 (95% CI 0.643-0.728).

CONCLUSION

Our data suggest that the logistic regression model can predict pathCR with a high probability. This clinical model could complement others (biomarkers) to predict pathCR.

摘要

背景

约 25%接受术前放化疗的食管癌(EC)患者可达到病理完全缓解(pathCR)。我们假设基于临床参数的模型可以预测 pathCR 的概率较高(≥60%)。

患者和方法

我们分析了 322 例接受术前放化疗的 EC 患者。所有患者均有基线期和放化疗后正电子发射断层扫描(PET),以及放化疗前和放化疗后内镜活检。采用逻辑回归模型进行分析,并通过自举法进行交叉验证来检验模型。

结果

70 例(21.7%)pathCR 的患者生存期更长(中位总生存期 [OS],79.76 个月),而 252 例未达到 pathCR 的患者生存期更短(中位 OS,39.73 个月;OS,P=0.004;无病生存期,P=0.003)。在逻辑回归分析中,以下参数有助于预测模型:放化疗后 PET、放化疗后活检、性别、组织学肿瘤分级和基线(EUS)T 期。受试者工作特征曲线下面积为 0.72(95%置信区间[CI] 0.662-0.787);经过 200 次重复的自举验证后,校正后的 AUC 为 0.70(95%CI 0.643-0.728)。

结论

我们的数据表明,逻辑回归模型可以高概率预测 pathCR。该临床模型可以补充其他(生物标志物)来预测 pathCR。